Close Menu

Invokana and Invokamet (Canagliflozin)

Invokana and Invokamet diabetic drugs have been linked to:

  • kidney injuries,
  • amputations,
  • diabetic ketoacidosis,
  • urinary tract and blood infections

The drugs are known as SGLT2 (Sodium-glucose cotransporter-2 inhibitors) that treat low blood sugar in adults with type 2 diabetes. Other drugs in this category include: Farxiga, Xigduo, Glyxambi, Jardiance, Synjardy.

Close to 1000 cases have been consolidated in MDL 2750 IN RE: INVOKANA (CANAGLIFLOZIN) PRODUCTS LIABILITY LITIGATION before Judge Brian Martinotti and Judge Lois Goodman. Invokana (canagliflozin) Products Liability Litigation.

FDA Warnings

In June 2016, the FDA added kidney warnings for Invokana, Invokamet (generic name Canagliflozin), Farxiga, and Xigduo XR, warning that the drugs were linked to adverse event reports of acute kidney injury that in some cases required hospitalization. Symptoms of kidney injury include decreased urine and swelling in the legs or feet. Some patients have filed Invokana kidney failure lawsuits, claiming that the manufacturer did not sufficiently warn of possible renal side effects.

In May 2017, the FDA added a black box amputation risk warnings after CANVAS (Canagliflozin Cardiovascular Assessment Study) revealed patients who took canagliflozin had a far higher rate of amputations than the patients in the placebo control group. 9 out of every 1,000 patients underwent an amputation in one clinical trial and another clinical trial revealed 5 out of every 1,000 patients on canagliflozin underwent an amputation.

Free Medical Legal Consultation

If you were prescribed Invokana and suffered an amputation of your toe, foot, or leg, and/or kidney injuries, contact us now for a free medical legal consultation.  Call us at 1-800-814-4540, email at or fill out the contact form to the right. We understand the pain, suffering and financial issues that overwhelm injured people, so contact us now before the time to file your claim runs out.

Share This Page:
Facebook Twitter LinkedIn Google Plus